Correction to Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (The Lancet Oncology (2017) 18(6) (732–742), (S1470204517303121)(10.1016/S1470-2045(17)30312-1));Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

The Lancet Oncology

Volumn 18, Issue 6, 2017, Pages 732-742

  Diéras, Véronique ^a   Miles, David ^b   Verma, Sunil ^c   Pegram, Mark ^d   Welslau, Manfred ^e   Baselga, José ^f   Krop, Ian E ^g   Blackwell, Kim ^h   Hoersch, Silke ⁱ   Xu, Jin ^j   Green, Marjorie ^j   Gianni, Luca ^k  

^a INSTITUT CURIE   (France)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d STANFORD CANCER INSTITUTE   (United States)

^e Medical Office Hematology   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j GENENTECH INC   (United States)

^k SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; LAPATINIB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TAXANE; TAXOID; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER SURVIVAL; CAUSE OF DEATH; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DECREASED APPETITE; DESCRIPTIVE RESEARCH; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HYPOKALEMIA; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PARONYCHIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HAND-FOOT SYNDROME; MIDDLE AGED; PATHOLOGY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; BRIDGED-RING COMPOUNDS; CAPECITABINE; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; HAND-FOOT SYNDROME; HUMANS; MALE; MAYTANSINE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; SURVIVAL RATE; TAXOIDS; THROMBOCYTOPENIA; TRASTUZUMAB; VOMITING; YOUNG ADULT;

EID: 85020027558     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30848-9     Document Type: Erratum

References (19)

1. Slamon, DJ, Clark, GM, Wong, SG, Levin, WJ, Ullrich, A, McGuire, WL, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987), 177–182.
2. Ross, JS, Slodkowska, EA, Symmans, WF, Pusztai, L, Ravdin, PM, Hortobagyi, GN, The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14 (2009), 320–368.
3. Dawood, S, Broglio, K, Buzdar, AU, Hortobagyi, GN, Giordano, SH, Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28 (2010), 92–98.
4. Slamon, DJ, Leyland-Jones, B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001), 783–792.
5. Marty, M, Cognetti, F, Maraninchi, D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23 (2005), 4265–4274.
6. Baselga, J, Cortés, J, Kim, SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366 (2012), 109–119.
7. Swain, SM, Kim, SB, Cortés, J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14 (2013), 461–471.
8. Geyer, CE, Forster, J, Lindquist, D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006), 2733–2743.
9. Lewis Phillips, GD, Li, G, Dugger, DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68 (2008), 9280–9290.
10. Verma, S, Miles, D, Gianni, L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 (2012), 1783–1791.
11. Therasse, P, Arbuck, SG, Eisenhauer, EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000), 205–216.
12. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, 2006 (accessed July 15, 2016).
13. Krop, IE, Kim, SB, González-Martín, A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15 (2014), 689–699.
14. Krop, IE, Kim, S-B, Gonzales Martin, A, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised phase 3 study. Lancet Oncol, 2017 published online May 16 http://dx.doi.org/10.1016/S1470-2045(17)30313-3.
15. Swain, SM, Baselga, J, Kim, SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372 (2015), 724–734.
16. Dzimitrowicz, H, Berger, M, Vargo, C, et al. T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. J Clin Oncol, 2016, 10.1200/JCO.2016.67.3624 published online June 13.
17. Welslau, M, Diéras, V, Sohn, JH, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 120 (2014), 642–651.
18. Cardoso, F, Costa, A, Norton, L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25 (2014), 1871–1888.
19. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast Cancer. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp, 2016 (accessed July 15, 2016).